Low starting dosage of infliximab with possible escalating dosage in psoriatic arthritis gives the same treatment results as standard dosage of adalimumab or etanercept: results from the nationwide Icelandic ICEBIO registry

Bjorn Gudbjornsson,1,2 Arni Jon Geirsson,3,4 Niels Steen Krogh5 1Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland; 2Faculty of Medicine, University of Iceland, Reykjavik, Iceland; 3Department of Rheumatology, University Hospital, Reykjavik, Iceland; 4Laeknasetrid - Medical C...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gudbjornsson B, Geirsson AJ, Krogh NS
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Psoriatic Arthritis outcome biological treatment routine care clinical nationwide registry Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/1a2d9fd70fe74e35857fdaad12c0dba2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1a2d9fd70fe74e35857fdaad12c0dba2
record_format	dspace
spelling	oai:doaj.org-article:1a2d9fd70fe74e35857fdaad12c0dba22021-12-02T05:11:33ZLow starting dosage of infliximab with possible escalating dosage in psoriatic arthritis gives the same treatment results as standard dosage of adalimumab or etanercept: results from the nationwide Icelandic ICEBIO registry2230-326Xhttps://doaj.org/article/1a2d9fd70fe74e35857fdaad12c0dba22018-05-01T00:00:00Zhttps://www.dovepress.com/low-starting-dosage-of-infliximab-with-possible-escalating-dosage-in-p-peer-reviewed-article-PTThttps://doaj.org/toc/2230-326XBjorn Gudbjornsson,1,2 Arni Jon Geirsson,3,4 Niels Steen Krogh5 1Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland; 2Faculty of Medicine, University of Iceland, Reykjavik, Iceland; 3Department of Rheumatology, University Hospital, Reykjavik, Iceland; 4Laeknasetrid - Medical Clinic, University of Iceland, Reykjavik, Iceland; 5Zitelab Aps, Copenhagen, Denmark Objective: To explore differences in response to a low dosage regimen of infliximab with an escalating dosage in comparison to a standard dosage of etanercept and adalimumab in patients with psoriatic arthritis (PsA). Methods: Biologically naïve PsA patients who were beginning anti-TNF-α therapy were selected from the ICEBIO registry. Demographics and clinical differences were compared in four treatment groups: infliximab <4 mg/kg; infliximab >4 mg/kg; etanercept or adalimumab at baseline and on follow-up (6 and 12 months, last visit). The Kruskal–Wallis rank sum test was used for comparison of the groups and the Wilcoxon test to compare the two infliximab dosage regimens. Results: One hundred and eighty-five patients (61% female) were identified; 84 patients received infliximab, 66 etanercept, and 35 adalimumab. A total of 19% of the patients treated with infliximab escalated their dosage ≥4 mg/kg. No significant differences were observed at baseline in respect to visual analog scale (VAS) pain, VAS fatigue, Health Assessment Questionnaire, C-reactive protein (CRP), numbers of swollen or tender joints, or Disease Activity Score (DAS) 28-CRP values. A similar treatment response was observed in all four treatment groups on follow-up. Conclusion: In respect to treatment effects, a low dosage of infliximab with possible escalating dosage is acceptable for the majority of PsA patients who are in need of biological treatment. Keywords: psoriatic arthritis, outcome, biological treatment, routine care, clinical nationwide registryGudbjornsson BGeirsson AJKrogh NSDove Medical PressarticlePsoriatic Arthritisoutcomebiological treatmentroutine careclinical nationwide registryDermatologyRL1-803ENPsoriasis: Targets and Therapy, Vol Volume 8, Pp 13-19 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Psoriatic Arthritis outcome biological treatment routine care clinical nationwide registry Dermatology RL1-803
spellingShingle	Psoriatic Arthritis outcome biological treatment routine care clinical nationwide registry Dermatology RL1-803 Gudbjornsson B Geirsson AJ Krogh NS Low starting dosage of infliximab with possible escalating dosage in psoriatic arthritis gives the same treatment results as standard dosage of adalimumab or etanercept: results from the nationwide Icelandic ICEBIO registry
description	Bjorn Gudbjornsson,1,2 Arni Jon Geirsson,3,4 Niels Steen Krogh5 1Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland; 2Faculty of Medicine, University of Iceland, Reykjavik, Iceland; 3Department of Rheumatology, University Hospital, Reykjavik, Iceland; 4Laeknasetrid - Medical Clinic, University of Iceland, Reykjavik, Iceland; 5Zitelab Aps, Copenhagen, Denmark Objective: To explore differences in response to a low dosage regimen of infliximab with an escalating dosage in comparison to a standard dosage of etanercept and adalimumab in patients with psoriatic arthritis (PsA). Methods: Biologically naïve PsA patients who were beginning anti-TNF-α therapy were selected from the ICEBIO registry. Demographics and clinical differences were compared in four treatment groups: infliximab <4 mg/kg; infliximab >4 mg/kg; etanercept or adalimumab at baseline and on follow-up (6 and 12 months, last visit). The Kruskal–Wallis rank sum test was used for comparison of the groups and the Wilcoxon test to compare the two infliximab dosage regimens. Results: One hundred and eighty-five patients (61% female) were identified; 84 patients received infliximab, 66 etanercept, and 35 adalimumab. A total of 19% of the patients treated with infliximab escalated their dosage ≥4 mg/kg. No significant differences were observed at baseline in respect to visual analog scale (VAS) pain, VAS fatigue, Health Assessment Questionnaire, C-reactive protein (CRP), numbers of swollen or tender joints, or Disease Activity Score (DAS) 28-CRP values. A similar treatment response was observed in all four treatment groups on follow-up. Conclusion: In respect to treatment effects, a low dosage of infliximab with possible escalating dosage is acceptable for the majority of PsA patients who are in need of biological treatment. Keywords: psoriatic arthritis, outcome, biological treatment, routine care, clinical nationwide registry
format	article
author	Gudbjornsson B Geirsson AJ Krogh NS
author_facet	Gudbjornsson B Geirsson AJ Krogh NS
author_sort	Gudbjornsson B
title	Low starting dosage of infliximab with possible escalating dosage in psoriatic arthritis gives the same treatment results as standard dosage of adalimumab or etanercept: results from the nationwide Icelandic ICEBIO registry
title_short	Low starting dosage of infliximab with possible escalating dosage in psoriatic arthritis gives the same treatment results as standard dosage of adalimumab or etanercept: results from the nationwide Icelandic ICEBIO registry
title_full	Low starting dosage of infliximab with possible escalating dosage in psoriatic arthritis gives the same treatment results as standard dosage of adalimumab or etanercept: results from the nationwide Icelandic ICEBIO registry
title_fullStr	Low starting dosage of infliximab with possible escalating dosage in psoriatic arthritis gives the same treatment results as standard dosage of adalimumab or etanercept: results from the nationwide Icelandic ICEBIO registry
title_full_unstemmed	Low starting dosage of infliximab with possible escalating dosage in psoriatic arthritis gives the same treatment results as standard dosage of adalimumab or etanercept: results from the nationwide Icelandic ICEBIO registry
title_sort	low starting dosage of infliximab with possible escalating dosage in psoriatic arthritis gives the same treatment results as standard dosage of adalimumab or etanercept: results from the nationwide icelandic icebio registry
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/1a2d9fd70fe74e35857fdaad12c0dba2
work_keys_str_mv	AT gudbjornssonb lowstartingdosageofinfliximabwithpossibleescalatingdosageinpsoriaticarthritisgivesthesametreatmentresultsasstandarddosageofadalimumaboretanerceptresultsfromthenationwideicelandicicebioregistry AT geirssonaj lowstartingdosageofinfliximabwithpossibleescalatingdosageinpsoriaticarthritisgivesthesametreatmentresultsasstandarddosageofadalimumaboretanerceptresultsfromthenationwideicelandicicebioregistry AT kroghns lowstartingdosageofinfliximabwithpossibleescalatingdosageinpsoriaticarthritisgivesthesametreatmentresultsasstandarddosageofadalimumaboretanerceptresultsfromthenationwideicelandicicebioregistry
_version_	1718400516498653184

Low starting dosage of infliximab with possible escalating dosage in psoriatic arthritis gives the same treatment results as standard dosage of adalimumab or etanercept: results from the nationwide Icelandic ICEBIO registry

Ejemplares similares